Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD ... and IL-13 inhibitor Dupixent (dupilumab ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

Ungar, MD, assistant professor of dermatology and director of the Rosacea & Seborrheic Dermatitis Clinic at Mount Sinai, spoke with Healio about: what’s new in pediatric atopic dermatitis ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do not address the multiple inflammatory pathways that cause its specific ...

The FDA has granted Fast Track designation to rezpegaldesleukin for the treatment of moderate to severe atopic dermatitis.

Atopic dermatitis ... When used for AD, especially if it's widespread or disabling, the drugs help reduce inflammation.

The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with moderate to severe atopic dermatitis when topical treatments do not ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...